Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
Status:
Recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well axitinib and avelumab work in treating patients with
adenoid cystic carcinoma that has come back or spread to other places in the body. Axitinib
may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Immunotherapy with monoclonal antibodies, such as avelumab, may help the body's immune system
attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Giving axitinib and avelumab together may help to control adenoid cystic carcinoma.